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Abstract 
Background:  Warfarin is the most frequently used oral anticoagulant 
worldwide and it is the oral anticoagulant of choice in South Africa for 
reducing thrombosis-related morbidity and mortality. However, the safety and 
efficacy of warfarin therapy depends mainly on careful monitoring and 
maintenance of the international normalized ratio (INR) within an optimal 
therapeutic range.  In the ACTIVE-W trial conducted across nine countries, 
South Africa had the poorest anticoagulation control with warfarin. This study 
showed that 86% of patients on warfarin therapy in the country have their time 
in therapeutic range below target. This was an indication of a very poor 
warfarin control in South Africa .The trial reported centre-specific differences 
within each country. It was however silent on these differences in South 
Africa. 
Aim: The aim of this study was to describe the profile and the anticoagulation 
outcomes of patients on warfarin therapy in a major warfarin clinic in Western 
Cape Province of South Africa.  
Setting: Victoria Hospital - a large district hospital in Cape Town, South 
Africa, which serves around eight hundred thousand people. 
Methods: A cross sectional review of clinical records of patients on warfarin 
therapy who attended the INR clinic from 01 January 2014 to 30 June 2014 was 
done.  Data analysis was done with STATA to generate appropriate descriptive 
data and groups were compared using non-parametric tests. 
Results:  Age range for male patients was between 29-85 years with median 
age of 62 years, while that of female patients was between 17-92 years with a 
median age of 66 years. 
 Atrial fibrillation (AF) was the commonest indication for warfarin use in this 
study and hypertension was the commonest co-morbidity amongst these 
patients. Only 48.5% (66 patients) achieved target therapeutic range as of 01 
July 2014, while 51.5% (70/136) of the patients were out of range. Patients who 
were non-alcohol users (88.9%) had better therapeutic control than those who 
consumed alcohol (9.6%).  There was a significant association between 
alcohol consumption and poor anticoagulation outcomes (p value <0.022). 
Unlike alcohol use, there was no statistical relationship between smoking 
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habit and target therapeutic range (P value = 0.198).  The study also showed 
that anticoagulation outcomes were better among the older age groups, male 
patients and in those with atrial fibrillation. The prevalence of thrombotic 
events while on warfarin treatment was 2.2%, while prevalence of 
haemorrhagic events was 14%. Most of the patients with bleeding events were 
on concurrent use of warfarin and other medications with potential drug 
interactions. 
Conclusion: In this study, patients who achieved target therapeutic control 
were less than the acceptable 60%. Bleeding complications were more 
common among patients on concurrent use of warfarin with other 
medications such as NSAIDS and simvastatin. Therefore, it is of utmost 
importance for health professionals to take note of drug-drug or drug-disease 
interactions among patients on warfarin and to monitor INR levels more 
frequently in patients who have to unavoidably be on concurrent use of   
medications with possible major interactions with warfarin. 
Keywords: Oral anticoagulant, anticoagulation outcomes, therapeutic control, 
percentage INR within target therapeutic range (%ITTR). 
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Introduction 
 Thrombosis  is responsible for about 1 in every 4 deaths worldwide, and it is a 
significant contributor to global disease burden and mortality.1,2,3 Oral anticoagulant 
therapy (OAT) reduces morbidity and mortality associated with thrombosis-related 
conditions.3The main treatment goal for anticoagulation therapy is to reduce the risk 
of thromboembolic disease in patients with atrial fibrillation (AF), mechanical heart 
valves, deep vein thrombosis (DVT) and pulmonary embolism (PE) 4,5 , while at the 
same time minimising the risk of bleeding as a result of toxicity. Available oral 
anticoagulants include the Vitamin K antagonists (VKAs) such as warfarin, and the 
newer/novel oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, 
apixaban, edoxaban and betrixaban.3  Each of the newer anticoagulants act by 
directly inhibiting an activated clotting factor  (either factor IIa or factor Xa).3 The 
pharmacological properties of the newer anticoagulants are more predictable than 
those of the VKAs, so routine monitoring of the anticoagulation effect is not 
required.6 In South Africa, out of the newer oral anticoagulants, only dagibatran and 
rivaroxaban are available, though only in private practice due to the high cost and 
they have shown equivalence and non-inferiority to warfarin in terms of 
anticoagulation .7,8  
Warfarin is the most frequently used oral anticoagulant worldwide and it is the oral 
anticoagulant of choice in South Africa .9, 10, 11 It interferes with the Vitamin K cycle 
by reducing the synthesis of active Vitamin K-dependent factors (factors II, VII, IX, X 
and protein C and protein S).3 Pharmacologically, the narrow therapeutic index and 
the highly variable toxic dose that characterizes warfarin, 9, 12, 13 constitute a 
challenge to its safe and effective use in clinical practice. Therefore, it is essential to 
apply best practice methods in initiation and management of patients on warfarin 
therapy. A  Cochrane review demonstrated that warfarin is a more effective and 
superior oral anticoagulant than combined use of Aspirin plus clopidogrel. 9, 14The 
duration of anticoagulation therapy with warfarin varies from 6 months in venous 
thrombosis, to lifelong therapy in cardiac indications or recurrent thrombosis 5.  
Globally, management of anticoagulation therapy represents a major challenge for 
clinical and laboratory services.12 The implications of poor management of warfarin 
therapy are of significance to both the patient and clinician. Poor INR monitoring can 
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result in toxicity, bleeding and increased mortality. The safety and efficacy of 
warfarin therapy depends mainly on careful monitoring and maintenance of the 
international normalized ratio (INR) within an optimal therapeutic range. 11 The 
importance of therapeutic monitoring of INR is further emphasized by the fact that 
warfarin therapy is contra-indicated in situations when INR monitoring is not 
feasible.12  
The recommended optimal/target therapeutic range for INR is 2.0 –3.0 for most of 
the disease indications and 2.0 - 3.5 for those with cardiac valve prosthesis.12, 13, 15 
Supra-therapeutic oral anticoagulant treatment (OAT) with warfarin, with a resultant 
effect of high INR, puts patients at risk of warfarin toxicity or bleeding.  On the other 
hand, sub-therapeutic anticoagulation and a sub-therapeutic INR may not protect 
warfarinized patients against thromboembolic disorder .5, 9, and 15  Studies have shown 
that warfarin is greatly under-prescribed; and this has resulted in increased 
morbidity and mortality among affected patients. 16, 17 In 1995, a report by the 
Agency for Health Care Policy and Research (AHCPR) indicated that warfarin was 
being greatly under-utilized, because physicians are not comfortable with its safe 
use and fear that the drug might cause bleeding.16 
 This under-utilization of warfarin due to lack of confidence from clinicians could be 
interpreted as compromising patient rights to optimal care. Studies have shown that 
warfarin prevents 20 strokes for every bleeding episode that it causes.16, 17 Thus, it 
can be deduced that the benefit of appropriate use of warfarin outweighs the risk of 
toxicity. 9, 14  The efforts to enhance safe warfarin therapy, aside from meticulous 
INR monitoring, involves patient education, good record keeping and rational drug 
prescription 9,18,20 . 
There are various factors that could lead to fluctuation in the international 
normalized ratio (INR) and also affect patient response to warfarin therapy. 11 These 
factors vary from poor compliance, dosage error, concurrent illness, liver and kidney 
dysfunction, concomitant use of other medications, dietary interactions, laboratory 
error and ageing. 11, 15,19 A study done in  Cape Town Metro East  on comparative 
evaluation of warfarin utilization at Wesfleur and Gugulethu Community Health 
facilities, confirmed inter-personal variability in patient response to warfarin therapy 
with race, gender, weight, concomitant morbidity and medications all contributing. 
Medications such as sodium valproate, beta-lactam antibiotics, NSAIDs and anti-
ulcer drugs appeared to alter warfarin response due to drug interactions. 11 Vitamin 
K rich diets, such as kale, broccoli, cauliflower, Brussels sprouts, green tea, spinach 
and many green leafy vegetables also influence effectiveness of warfarin and 
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concurrent use of oral antibiotics (azithromycin, levofloxacin, and 
trimethoprim/sulphamethoxazole) with warfarin had been linked with high incidence 
of over-anticoagulation.10, 11, and 24.  
Time-in-therapeutic range (TIR) is a recommended measure of outcomes of oral 
anticoagulation management and a good way of evaluating the quality of 
management of an anticoagulation clinic. 15, 25 The TIR  can be calculated by  3 
methods : fractions of INR in range, point prevalence (i.e. cross-section of the files), 
and the Rosendaal method.20,25 The British Committee for Standards in 
Haematology(BCSH) recommends that international normalised ratio(INR) should 
be within target  therapeutic range at least 60% of time ( i.e. TIR of 60%).20  
Aside from the cost of treating warfarin adverse effects, the increasing levels of 
medical litigation in South Africa (and globally) is of concern to clinicians.  
Complications associated with over- or under-anticoagulation with warfarin could 
constitute a reason for litigation of health professionals. In the UK, the National 
Health Service (NHS) Litigation Authority has reported that anticoagulants are one of 
the ten most common drugs involved in errors resulting in claims against NHS 
trusts.20 However; most of these adverse effects are preventable. In South Africa, 
with the imminent introduction of the national health insurance (NHI) into the 
healthcare system, it is imperative to minimize adverse events associated with 
anticoagulation (warfarin) therapy by improving quality of care. There are several 
designated anticoagulation clinics across South Africa. A major concern however is 
that most of these centres do not have data on their therapeutic outcomes, the 
number of adverse events and bleeding incidents, in order to ensure better 
anticoagulation outcomes. Such records are important to positively impact decision 
and policy making towards optimal anticoagulation therapy. The researcher hopes 
that this study will improve awareness about the importance of proper oral 
anticoagulation and result in implementation of monitoring this service, firstly in the 
Western Cape and then in the rest of South Africa.Hence, the motivation for the 
researcher to conduct a study on the profile and anticoagulation outcomes of 
patients on warfarin therapy in a specific centre in Cape Town.   
The aim of the current study therefore was to evaluate the patient profile and 
anticoagulation outcomes of patients on warfarin in an urban hospital in Cape Town.  
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Research Method  
Study design: The study was conducted using a retrospect ive,  cross-
sectional, descriptive study model. It consisted of review of clinical records of 
patients who were on warfarin therapy.  
Study Population: The study population comprised of patients attending the 
anticoagulation Clinic at Victoria Hospital – a large district hospital situated in 
Wynberg, Cape Town in the Western Cape Province, South Africa.  
Sampling method: All patients who attended the anticoagulation clinic over a 
period of six months, between 01 Jan 2014 to 30 June 2014 were selected from the 
clinic attendance register. These included both old and new patients on oral 
anticoagulation therapy. 
  The study population included 161 patients, who attended the clinic within the 
study period. Twenty three (23) patients were excluded from the study, because 
they were less than 30 days on warfarin therapy. Thus anticoagulation effects of 
warfarin could not be accurately measured. There were two missing folders, which 
could not be accounted for. The remaining 136 patients (59 males and 77 females) 
were included in the study, because of the small sample size and in order to avoid a 
selection bias. 
 Data collection method: The folders were retrieved from the records department 
and a thorough review of the clinical record notes, treatment charts and 
anticoagulation record charts was conducted using a data extraction tool. 
Parameters such as age, sex, social habits, treatment indications, existing co-
morbidities, INR records, warfarin use with other medications with potential drug 
interactions and adverse events (bleeding and thrombotic complications) were 
extracted for the period from 01 January to 30 June 2014. The last INR prior to 01 
July 2014 for each study participant was used to categorize anticoagulation 
outcomes into target therapeutic range (INR 2.0 – 3.0 or 2.5 -3.5 in patients with 
mechanical valve heart replacement), sub-therapeutic range (INR <2.0 Or < 2.5 in 
patients with mechanical heart valve replacement) and supra-therapeutic (INR >3.0 
0R >3.5 in patients with mechanical heart valve replacement). 
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Anticoagulation outcomes were calculated by finding the percentage of patients with 
last INR within target therapeutic range (%ITTR) and percentage of patients with last 
INR out-of therapeutic range by using cross section-of-the-files method. This 
method assesses therapeutic control by taking the last INR of each patient before a 
pre-specified assessment date. The pre-specified assessment date for this study 
was 01 July, 2014. The most commonly used method of assessing anticoagulation 
outcome is the Rosendaal method, but it is very difficult to use in a non-
computerised setting. 21 Thus, cross sectional method was used in this study. 
Statistical analyses 
Distribution of continuous data were analysed graphically or by Shapiro-Wilk test 
and then the appropriate statistical methods were employed (parametric if normally 
distributed and non-parametric if skewed). Wilcoxon rank-sum test was used in 
comparing two medians, while Fisher’s exact test was used for categorical data 
when the expected frequency in cells is < 5. 
Due to the skewed age distribution, median age and range were analysed. 
Differences in  age and sex distribution were tested by using two sample Wilcoxon 
rank-sum (Mann-Whitney U) test, while statistical association between %ITTR , age  
and  gender distribution were tested using a Fisher’s exact test. Statistical 
relationship between %ITTR and various indications for warfarin, co-morbidities and 
concurrent use of warfarin with medications with potential drug interactions were 
analysed with Mann-Whitney U test.  Statistical association between % ITTR and 
bleeding/thrombotic events were tested with a Fisher’s exact test, while relationship 
between age and adverse events were done by using a Mann-Whitney U test.  
Statistical relationship between % ITTR and social habits (smoking and alcohol use) 
were analysed by using a Kruskal-Wallis test.  
 All statistical tests were two-sided. The P-value threshold for significance was 
<0.05. 
Ethical Consideration 
The necessary ethics approval was obtained from the University of Cape Town 
Human Research Ethics Committee (HREC REF: 608/2014), Western Cape 
provincial research ethics committee (WC_2014RP50_937) and the management of 
Victoria Hospital. There was no conflict of interests and no external source of 
funding.  
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Results 
1. Age and  sex distribution of patients 
Total number of patients recruited was 136, 59 Males (43.4%) and 77 Females 
(56.6%). Age range for males was between 29-85 years with median age of 62 
years, while that of females was between 17-92 years with a median age of 66 
years. There was a significant difference in the age distribution of patients on 
warfarin therapy (P value < 0.029), with highest number of warfarin users (33.1%) 
falling between ages of 60-69yrs in both sex (24 males and 21 females), and while 
the lowest number of users (6.6%) were below age 39 years. There was no 
statistical difference in the sex distribution among the patients who were on warfarin 
treatment (p value < 0.179) (as shown in table 1).  
2. Social habits 
Alcohol consumption habit  
 Out of the 136 patients, 88.9% (121) of patients were non-alcohol consumers, while 
9.6 % (13) of patients consumed alcohol and 1.5% (2) of patients had no alcohol 
history recorded.  Out of the 13 patients who were alcohol users, four had their INR 
values within target therapeutic range (ITTR) .However, patients who consumed 
alcohol had lower %ITTR compared to the non-alcohol users. There was a 
significant association between alcohol consumption and poor anticoagulation 
outcomes (p value <0.022) (Table 2). 
 Smoking habit of patients  
Out of the 136 patients, 77.9% (106) of patients were non-smokers, while 19.9% 
(27) were smokers. Record of smoking habit was not documented in 3 (2.2%) 
patients. Unlike alcohol use, there was no statistical relationship between smoking 
habit and target therapeutic range (P value = 0.198) (Table 3). 
       3.        Co-morbidities among patients on Warfarin therapy 
Hypertension was the commonest co-morbidity among the study population. Out of 
the 136 study population, 95 were hypertensive. Other common comorbidities 
include diabetes mellitus (37), ischaemic heart disease (35), congestive cardiac 
failure (34), dyslipidaemia (28) and stroke (17). Other less common  comorbidities 
among the patients include gout (16), Chronic obstructive pulmonary disease 
(COPD) (14), arthritis (8), pulmonary tuberculosis (8), hypothyroidism (6), 
hyperthyroidism(3), chronic liver disease(2), peptic ulcer disease(1) and HIV/AIDS : 
positive (6), negative (15), not tested (115) (Table 4).  
4.          Indications for Warfarin 
Atrial fibrillation (AF) was the commonest indication for warfarin use among the 
study population. Out of the 136 patients in the study, 65% of patients have atrial 
fibrillation as an indication for warfarin use. Other indications for warfarin use among 
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the study population include alular heart disease (16.9%), mechanical heart valve 
replacement (13.2%), DVT (13.2%), recurrent DVT (9.6%), pulmonary embolism 
(8.1%), hypercoagulation (2.9%) and atrial flutter (4.4%)  
5.          Anticoagulation outcomes (Cross sectional method) 
Out of 136 patients, 66 (48.5%) had INR values within target therapeutic range as of 
01 July 2014. The result showed that a total of 51.5% (70/136) of the patients were 
out of range; of which 41.2% (56) were sub-therapeutic, while 10.3% (14) were 
supra-therapeutic (Figure 1). 
6.       Relationship between sex and anticoagulation outcomes. 
 The study also showed that males (50.8%) have relatively higher INR within target 
therapeutic range than females (46.8%)  
7.       Relationship between anticoagulation outcomes and age   
In the study population, ITTR is higher among those who are 60years and above.  
8.       Adverse Events while on warfarin therapy 
Out of the 136 sampled population, a total of nineteen patients (14%) had bleeding 
events (7 males and 12 females).The highest number of bleeding events occurred in 
both sexes among older age groups, 60years and above. These correspond with 
same age group with higher % ITTR. Thrombotic events occurred in 3 patients 
(2.2%). The events occurred in those within age range 40-49 years (one male) and 
60-69 years (a male and a female).  
9. Concurrent use of warfarin with other medications with potential drug 
interactions.  
A total of 87 patients were on concurrent medications with possible drug interactions 
with warfarin (as shown in table 9). The most commonly used among such 
medications are simvastatin (57) and Aspirin (35). Out of   the 57 patients that were 
concurrently using simvastatin with warfarin, 7  reported bleeding events, while 5 
patients out the 35 patients with concurrent use of  warfarin with Aspirin also had 
bleeding events. Other medications with potential drug interactions that were used 
concurrently with warfarin include amiodarone (7), sodium valproate (3), 
methotrexate (1), allopurinol (8), SSRIs (1) and digoxin (12).  One of the patients on 
amiodarone also reported a bleeding complication. 
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Discussion  
 Despite the challenges associated with its use, warfarin remains the standard 
anticoagulation medication in patients with thrombotic-related conditions. Several 
factors, including genetic differences have made it difficult to apply findings of 
studies across different populations. Studies that evaluate warfarin therapy along 
with anticoagulation outcomes among different patient groups are scarce in South 
Africa. The findings of the current study present important insights into expectations 
in the larger South African society. Our study reported poor anticoagulation 
outcomes among the study population. From the result, percentage INR within 
target therapeutic range (% ITTR) was 48.5%. This implied that less than half of the 
patients achieved optimal therapeutic outcome. A similar study in Ethiopia reported 
that only 30.8% of patients on warfarin had INR values within target therapeutic 
range (%ITTR), while 69.7% of patients were out-of range.24 These anticoagulation 
reports from Africa were relatively poor outcomes when compared to a similar study 
in Europe, in which Barbui et al reported a %ITTR of 71% among patients in Italy.22 
In a trial conducted in nine countries ,with South Africa as one the study participants 
, the ACTIVE W trial gave an insight into the extent of poor anticoagulation 
outcomes in South Africa. The report of the trial, showed that 86% of  South African 
patients who were  entered as participants  into the trial have INR that were out-of- 
therapeutic range 60% of the time while on warfarin therapy.14 In this study, 51.5% 
of the patients were out-of-range while on warfarin treatment. It was also observed 
in this study that patients who were out-of-range were four times more likely to be 
sub-therapeutic than being over-therapeutic. In line with this finding, a similar study 
in Sweden showed that patients who were out-of-range were twice likely to be sub-
therapeutic than over-therapeutic .21 But , contrary to this finding, Teklay et al, 
reported in a similar study in Ethiopia, that patients who were out-of-range were 
more in the supra-therapeutic range .24 
Our study showed a statistically significant difference in age distribution of patients 
on warfarin therapy in our setting. The age distribution skewed more towards the 
older age group. This is not unexpected, as more patients develop AF as they get 
older. Patients who were on warfarin treatment cut across different age groups.  
Most of the patients significantly fall between the age of 60-69years in both males 
and females (p value 0.029).  There were more females (77/136) on warfarin 
therapy than males (59/136), probably because more women make use of the 
health facility than men. The characteristics of patients on warfarin treatment in this 
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study population were similar in terms of age and gender distribution compared with 
other studies that were conducted in Cape Town and in other countries.11, 14, 21,22,23,24 
This study reported higher %ITTR among the older age groups, who were 60years 
and above. This means that patients above 60years have more INR values within 
target range and this implied a better anticoagulation outcome among the older age 
groups. A similar study   in Sweden was in support of  this finding and showed that 
there were  significant correlations  between time in  therapeutic range(TIR) and 
increasing age (P <0.001), 23 and that the mean dose of warfarin required  
decreases with advance age ,while the time spent in therapeutic range  increased 
with age .23 
From the study, the result also showed that male patients have better therapeutic 
control than the female patients. There were more male patients with their INR 
values within target therapeutic range than female patients (Table 6).This 
observation is line with the result of a similar study in Sweden, which reported that 
males have better anticoagulation outcomes than females .21 There was no sound 
explanation for this gender-based difference in therapeutic outcomes of   patients 
who were on warfarin treatment. But, it could probably be as a result of consumption 
of more vitamin K-rich diets (such as green leafy vegetables) by female patients. 
The most common indication for warfarin in our setting is atrial fibrillation (AF). 
Similar studies conducted in South Africa and other countries in Europe and 
America were in agreement with this finding .4, 11,21,22,23   AF is the most common 
cardiac arrhythmia worldwide .26  A systematic review of worldwide population-
based studies estimated that the number of individuals with AF in 2010 was 33.5 
million and that there are about 5 million new cases each year.26  AF increases the 
risk of thromboembolic stroke by 5% and warfarin treatment reduces the risk  by 
68%.4,5,8,12,13 Studies have shown that the effectiveness of warfarin in atrial 
fibrillation is reduced when INR drops below 2.0 and the effectiveness is intrinsically 
lost whenever   INR value falls below 1.5.15 In our study, it was observed that 
patients with AF have higher %ITTR than other patients who were on warfarin for 
other indications as shown in table 5. This implied a relatively better anticoagulation 
outcome in patients who were on warfarin treatment due to atrial fibrillation. This 
finding is in agreement with the report of a similar observational study that was 
conducted in Italy, in which Pole et al described a better therapeutic control in 
patients with an AF than in patients with venous thromboembolism.22  
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Studies have reported that inter-individual variability and possible influence of 
comorbidities may affect response of patients to anticoagulation therapy .11 The 
commonest comorbidity among patients on warfarin in our study is hypertension. 
Chronic hypertension has been associated with complications such as AF, which 
has been identified as the commonest indication for warfarin therapy in our study. 
The role of   hypertension  in the epidemiology of  AF is further emphasized by the 
fact that  hypertension and valvular heart disease have been identified as  the most 
common  risk factors for AF globally .27 In future research, there may be a need to 
establish the impact of different comorbidities on patient response to warfarin 
therapy in our setting. It is also recommended that future researchers should look 
into the relevance of depressive illness on anticoagulation outcomes.   
 In this study, the effects of social habit on anticoagulation outcomes were 
described.  The result showed a significant association between alcohol 
consumption and poor anticoagulation outcome (P value <0.022).  Patients who 
consumed alcohol had lower %ITTR compared to the non-alcohol users (Table 2).  
Studies have shown that heavy alcohol consumption potentiates the anticoagulation 
effects of warfarin by increasing the INR and thereby increases the risk of 
bleeding.28 However, alcohol consumption within normal limits is safe .28 It is 
therefore important to educate patients who were taking warfarin to refrain from 
excessive alcohol use and for health professionals to document the quantity of 
alcohol consumed into the record of patients who consume alcohol. Unlike alcohol 
use, in our study, there was no statistical association between smoking habit and 
%ITTR (p value = 0.198) (Table 3). In a similar study, Whitley and colleagues 
reported that there was no association between cigarette smoking and warfarin 
dose.29   Despite the fact that cigarette smoking has been associated with increased 
metabolism of several drugs, its effect on warfarin metabolism is not clearly 
established .29, 30, 31 However, smoking is an established vascular risk factor, which 
can independently increase the risk of thrombotic events.  Almost 40% of smoking-
related deaths are associated with cardiovascular disease.30  
Mann Whitney test was used to compare association between bleeding events and 
increasing age, our study showed a statistically significant association between 
older age groups and bleeding events (P < 0.007). In this study, the highest number 
of bleeding events occurred among the older age groups above 60years in both 
sexes as shown in table 8. This finding is in agreement with other similar studies on 
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warfarin, in which it had been reported that the incidence of both bleeding and 
thromboembolic events increases sharply with advanced age. 21,22,23,33 
 In our study, despite the fact that 41.2% of   the INR results were sub-therapeutic, 
the prevalence of thrombotic events while on warfarin treatment was as low as 
2.2%, while prevalence of haemorrhagic events was 14%.However, it is not 
impossible that some of these adverse events were not documented.  In a similar 
study, Teklay et al reported haemorrhagic rate of 16.5% among patients in 
Ethiopia24, while Zhang et al reported a prevalence of 14.7% .35. In this study, all the 
haemorrhagic events occurred when the INR values were supra-therapeutic. This 
finding is in support of a Norwegian study, which reported that 74% of   patients who 
were on warfarin were supra-therapeutic at the time of   bleeding event.36 In our 
setting, it was observed that, out of the 19 patients that reported bleeding events, 5 
were on concurrent use of   warfarin and aspirin and 7 were on concomitant use with 
simvastatin (Table 9). Although, this study did not assess the degree of drug 
interactions, many studies have reported that concurrent use of NSAIDs with aspirin 
increases the risk of serious bleeding .24, 34, 35 Studies have also shown that 
simvastatin has the potential of enhancing the effects of warfarin by inhibiting 
warfarin metabolism through inhibition of P450 enzymes and this might also 
increase the risk of bleeding .37, 38 
Strengths and limitations 
This study did not measure the actual time that each patient spent in therapeutic 
range. The cross sectional method used in this study only assessed a snapshot of 
the anticoagulation outcomes in the clinic at a specific period of time. This may not 
be a true reflection of what happened in the past. Also, this study did not quantify 
the amount of   alcohol / cigarette consumed by the patients as this information was 
not recorded in almost all the folders that were reviewed. The advantage of the 
cross sectional method used in assessing the anticoagulation outcomes is that the 
method considers individual patients and it is not influenced by percentage of INRs 
out-of–range.  
Future research should perhaps compare anticoagulation outcomes of patients 
attending primary health care based anticoagulation clinic and those attending 
hospital based anticoagulation clinic. 
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Conclusion 
In this study, patients who achieved target therapeutic control were less than the 
acceptable 60%. Anticoagulation outcomes were better among the older age groups 
and in those with atrial fibrillation. Bleeding complications were more common 
among patients on concurrent use of warfarin with other medications such as 
NSAIDS and simvastatin. Therefore, it is of utmost importance for health 
professionals to take note of drug-drug or drug-disease interactions among patients 
on warfarin and to monitor INR levels more frequently in patients who have to 
unavoidably be on concurrent use of   medications with possible major interactions 
with warfarin. 
 The researcher  recommend  point- of-care INR testing ,implementation of  
standardized anticoagulation guidelines in all anticoagulant clinics across the 
country  and a computerized warfarin dose adjustment  that will aid health 
professionals in taking  appropriate actions on abnormal INR levels. Implementation 
of these recommendations will go a long way in enhancing good anticoagulation 
outcomes among the patients on warfarin therapy in our setting. Patient education 
and counselling about warfarin therapy should also be given a priority during 
initiation of warfarin; such as it has been the standard practice before the initiation of 
patients on antiretroviral drugs, which had yielded a huge success in South Africa. 
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Tables and figures 
 
Table 1:  Age and sex distribution among study population (n=136). 
Age 
distribution(years) 
             Female                    Male                 Total 
 Frequency Percentage Frequency Percentage Frequency Percentage 
39 and below 5 6.5 4 6.8 9 6.6 
40 – 49 9 11.7 6 10.2 15 11.0 
50 -59 12 15.6 11 18.6 23 16.9 
60 – 69 21 27.3 24 40.7 45 33.1 
70 - 79  19 24.7 11 18.6 30 22.1 
 80 and above 11 14.2 3 5.1 14 10.3 
Total 77 56.6 59 43.4 136 100 
Median ( Range) 66(17- 92)  62(29- 85)    
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Table 2: Alcohol consumption profile among study population 
Alcohol use Frequency among 
patients  
Percentage 95% Confidence 
interval 
No 121 88.9 82.4 - 93.3 
Yes 13 9.6 5.6 - 15.9 
Unknown 2 1.5 0.4 - 5.8 
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Table 3: Smoking profile 
Smoking habit Frequency among 
patients  
Percentage    95% Confidence 
interval 
No 106 77.9 70.1 - 84.2 
Yes 27 19.9 13.9 – 27.5 
Unknown 3 2.2 0.7 – 6.7 
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Table 4: Comorbidities among the patients (n =136). 
 
Comorbidities   Frequency 
Hypertension   95 
Diabetes mellitus  37 
Congestive cardiac failure (CCF)  34 
Chronic obstructive airway disease(COPD)  14 
Arthritis  28 
Peptic ulcer disease (PUD)   1 
Tuberculosis (TB)   8 
HIV    6 
Liver disease   2 
Gout   16 
Hyperthyroidism  3 
Hypothyroidism   6 
Ischaemic heart disease (IHD)  35 
Stroke  17 
Dyslipidaemia  28 
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Table 5: Indication for warfarin use in patients (n = 136).  
Indication Number  of 
patients 
Percentage  Number of 
patients with INR 
within target 
therapeutic range 
 ITTR (%) 
Deep vein 
thrombosis(DVT) 
18 13.2 8 44.4 
Recurrent DVT 13 9.6 
 
6 46.1 
Pulmonary 
embolism 
11 8.1 3 27.3 
Heart valve disease 23 
 
16.9 9 39.1 
Mechanical heart 
valve replacement 
18 13.2 8 44.4 
Atrial fibrillation(AF) 
 
88 64.7 46 52.3 
Atrial flutter 
 
6 4.4 2 33.3 
Hyper-coagulation 
 
4 2.9 2 50.0 
Cardiomyopathy/LV 
thrombosis 
 
9 6.6 3 33.3 
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Table 6: Relationship between anticoagulation outcomes and sex. 
Anticoagulation 
outcomes 
                    Male                   Female                    Total 
Therapeutic category Number 
of patients 
  TR (%) Number of 
patients 
 TR (%) Number of 
patients 
ITTR (%) 
Target therapeutic 
range 
30 50.8 36 46.8 66 48.5 
Sub-therapeutic 24 40.7 32 41.6 56 41.2 
Supra-therapeutic 5 8.5 9 11.7 14 10.3 
Total 59 100 77 100 136 100 
 
Fisher’s exact test: comparing relationship between sex and percentage INR within target therapeutic 
range (%ITTR). 
P value = 0.798: Time in therapeutic range and sex are not statistically related. 
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Figure 1: Anticoagulation outcomes of patients on warfarin 
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Table 7:  Relationship between age and percentage INR within target therapeutic range 
Age 
Distribution 
Total  
number 
of 
patients  
Number  of 
patients 
within 
target 
therapeutic 
range   
% of 
patients 
with INR 
within 
target 
therapeutic 
range          
( %ITTR) 
Number  of 
patients in 
Sub-
therapeutic  
range 
% of 
patients in 
Sub-
therapeutic  
range 
Number  of  
patients in  
Supra-
therapeutic 
range 
% of 
patients in 
supra-
therapeutic  
Range 
39 and 
below 
9 4 44.4 5 55.6 0  0.0 
40 – 49 15 7 
 
46.7 6 40.0 2  13.3 
50 – 59 22 9 40.9 
 
8 36.4 5  22.7 
60 – 69 46 23 50.0 20 
 
43.5 3  6.5 
70 – 79 30 15 50.0 
 
13 43.3 2  6.7 
80 and 
above 
14 8 57.1 
 
4 28.6 2  14.3 
Total  136 66 48.5 
 
56 41.2 14  10.3 
 
Fisher’s exact test: P value = 0.761 
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Table 8: Relationship between adverse events and sex 
                 
                   Males  
               
                        Females 
                   
                            Total 
Age 
interval  
 Aga 
Frequ
ency 
n(ble
eding 
n(thrombot
ic) 
 
Frequenc
y 
n(blee
ding) 
n(thromb
otic) 
Freque
ncy 
n(blee
ding) 
% n(throm
botic) 
% 
39 or  
 
below 
2 0 0 5 0 0 4 0 0.0 0      
0.0 
40 – 49 
 
 
6 1 1 9 0 0 15 1 6.7 1       
6.7 
50 – 59 
 
 
11 0 0 12 1 0 23 1 4.3 0      
0.0 
60 – 69 
 
 
24 4 1 21 2 1 45 6 13.3 2      
4.4 
70 – 79 
 
 
11 1 0 19 6 0 30 7 23.3 0       
0.0 
80 and  
 
 above 
3 1 0 11 3 0 14 4 28.6 0       
0.0 
Total  
 
 
59 7 2 77 
 
12 1 136 19 14.0       3 2.2 
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Table 9: Concurrent warfarin use with other medications with potential drug interactions 
 
Concurrent  drug use Number of patients on the drug Number of bleeding events 
Amiodarone 
 
7 1 
Simvastatin 
 
57 7 
Valproate 
 
3 0 
Methotrexate 
 
1 0 
Salicylates 
 
35 5 
Allopurinol 
 
8 0 
SSRIs 
 
1 0 
NSAIDS 
 
11 0 
Digoxin 
 
12 0 
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